Rudy Navari

Rudy Navari

Medical Oncology


Dr. Navari received the Ph.D. degree at the University of Virginia, and the M.D. degree at the Medical College of Virginia. He received training in internal medicine at the University of Alabama, and was a Fellow in Hematology and Oncology at the Fred Hutchinson Cancer Research Center. He joined the faculty of Notre Dame in 1999 as Director of the Walther Cancer Research Center. He was appointed Associate Dean, College of Science, in 2000. In 2005, he became Professor of Medicine, Assistant Dean and Director, Indiana University School of Medicine South Bend.

Research Interests

Rudolph Navari’s research program involves several important issues aimed at improving quality of life of people living with cancer, including cancer-related anorexia (CRA), depressive symptoms in breast cancer patients, and the effect of religious practices and spiritual beliefs on end-of-life care decisions.

Navari’s research has shown that the use of olanzapine, an antiemetic agent, and megestrol acetate appears to be an effective intervention for patients with CRA. Further clinical studies have revealed that olanzapine in combination with palonosetron can prevent chemotherapy-induced nausea and vomiting. In a Phase II research trial, the combination of olanzapine and palonosetron with dexamethasone given only on the day of chemotherapy was safe and highly effective.

In another investigation, breast cancer patients had significant improvement in the completion rate of initial adjuvant treatment, quality of life, and depressive symptoms with the use of fluoxetine. Another of his studies, with 339 adults with advanced cancer, showed that those with advanced directives were more likely to be active in religious or spiritual practices, although they had little knowledge of their religion’s recommendations on end-of-life care.

Recent Publications

  • Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz, Swearingen A, Navari RM, Ploplis V, Castellino FJ. Blood component therapy in trauma guided with the Utilization of the perfusionist and thromboelastography. J ExtraCorporeal Technology,  43: 162-67, 2011. 
  • Navari RM, Gray SE, Kerr AC Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV): A randomized phase III trial.  J Supp Oncol, 9: 188-195, 2011. 
  • Navari RM, Province PS, Passik, SD Management of Nausea and Vomiting in Cancer Patients.  in Cancer Management in Man: Biological Response Modifiers, Chemotherapy, Biological therapy, Hyperthermia, and Supporting Measures B Minev, (ed.), pp 453-71, Springer Academic Publishers, N.Y., 2011.
  • Castellino FJ, Donahue DL, Navari RM et al. An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood, 117: 283-289, 2011. 
  • Navari RM Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncology, 6:1073-84, 2010. 

Contact Information

  • Adjunct Professor
  • Office: 100H Harper
  • Phone: 574-631-3793
  • Send an email